Article actualité
Les articles d'actualités, brèves, dépêches et news du moment.
Les articles plus construits doivent aller dans la section "Dossiers".
Écrit par APO
|
14 Juillet 2017
Independent trials in Benin, Burkina Faso, Tanzania and Ivory Coast have proven the efficacy of Interceptor G2 and Sylando 240SC against local insecticide-resistant mosquitoes
LIMBURGERHOF, Germany, July 13, 2017/
WHO recommendation for game-changing mosquito net.First bed net to contain non-pyrethroid chemistry.Collaboration with IVCC and London School of Hygiene & Tropical Medicine...
Écrit par WILEY
|
14 Juillet 2017
Hoboken, NJ —July 13, 2017 — John Wiley and Sons, Inc. (NYSE:JWa) (NYSE:JWb), is pleased to announce a new partnership with the International AIDS Society (IAS) to publish their fully open access journal, Journal of the International AIDS Society (JIAS). JIAS is well-established with an Impact Factor of 6.296, and all articles in the journal are open access and free to view, download...
Écrit par NIHR
|
14 Juillet 2017
University of Warwick researchers are to improve the lives of India’s millions of psychosis sufferers.
The National Institute of Health Research’s (NIHR) Global Health Research Unit has awarded the University’s Warwick Medical School £1.5 million (almost USD 2 million) to work with this highly vulnerable and disadvantaged group. The award will be used to improve their health...
Écrit par GlobalData
|
14 Juillet 2017
The acute myeloid leukemia (AML) market across the seven major countries (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will more than triple from $406 million in 2016 to over $1.5 billion by 2026, representing a compound annual growth rate of 14%, according to research and consulting firm GlobalData.
The company’s latest report states that major drivers of the AML...
Écrit par Guerbet
|
10 Juillet 2017
Villepinte, le 10 juillet 2017 (7h00) - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, annonce aujourd'hui qu'il va cesser progressivement la commercialisation de deux produits : Hexabrix® (ioxaglate de meglumine et de sodium) et Optimark® (gadoversétamide).
Suite à l'acquisition de l'activité de produits de contraste...
